Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;35(9-10):317-328.
doi: 10.1089/hum.2024.022. Epub 2024 Apr 8.

Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases

Chujiao Lin  1 , Matthew B Greenblatt  2   3 , Guangping Gao  4   5   6   7 , Jae-Hyuck Shim  1   4   7
Affiliations
Review

Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases

Chujiao Lin et al. Hum Gene Ther. 2024 May.

Abstract

Adeno-associated viral (AAV) vectors have emerged as crucial tools in advancing gene therapy for skeletal diseases, offering the potential for sustained expression with low postinfection immunogenicity and pathogenicity. Preclinical studies support both the therapeutic efficacy and safety of these vectors, illustrating the promise of AAV-mediated gene therapy. Emerging technologies and innovations in AAV-mediated gene therapy strategies, such as gene addition, gene replacement, gene silencing, and gene editing, offer new approaches to clinical application. Recently, the increasing preclinical applications of AAV to rare skeletal diseases, such as fibrodysplasia ossificans progressiva (FOP) and osteogenesis imperfecta (OI), and prevalent bone diseases, such as osteoporosis, bone fracture, critical-sized bone defects, and osteoarthritis, have been reported. Despite existing limitations in clinical use, such as high cost and safety, the AAV-mediated gene transfer platform is a promising approach to deliver therapeutic gene(s) to the skeleton to treat skeletal disorders, including those otherwise intractable by other therapeutic approaches. This review provides a comprehensive overview of the therapeutic advancements, challenges, limitations, and solutions within AAV-based gene therapy for prevalent and rare skeletal diseases.

Keywords: AAV; Gene Therapy; Skeletal Diseases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol 2017;4(1):46–56. - PMC - PubMed
    1. Borumandi F, Aghaloo T, Cascarini L, et al. . Anti-resorptive drugs and their impact on maxillofacial bone among cancer patients. Anticancer Agents Med Chem 2015;15(6):736–743. - PubMed
    1. Grech A, Breck J, Heidelbaugh J. Adverse effects of testosterone replacement therapy: An update on the evidence and controversy. Ther Adv Drug Saf 2014;5(5):190–200. - PMC - PubMed
    1. Miller PD, Hattersley G, Riis BJ, et al. . Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA 2016;316(7):722–733. - PubMed
    1. Eastell R, Rosen CJ, Black DM, et al. . Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab 2019;104(5):1595–1622; doi: 10.1210/jc.2019-00221 - DOI - PubMed

Publication types

LinkOut - more resources